Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Register Financial Advisors LLC

Register Financial Advisors LLC cut its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 14.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 342 shares of the medical research company’s stock after selling 59 shares during the quarter. Register Financial Advisors LLC’s holdings in Thermo Fisher Scientific were worth $199,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Fifth Third Wealth Advisors LLC boosted its position in Thermo Fisher Scientific by 24.3% during the first quarter. Fifth Third Wealth Advisors LLC now owns 2,397 shares of the medical research company’s stock worth $1,393,000 after acquiring an additional 469 shares during the last quarter. Dohj LLC acquired a new position in Thermo Fisher Scientific during the first quarter worth about $600,000. Lockerman Financial Group Inc. purchased a new position in Thermo Fisher Scientific during the first quarter worth about $217,000. Thrive Wealth Management LLC raised its stake in Thermo Fisher Scientific by 12.2% during the first quarter. Thrive Wealth Management LLC now owns 3,119 shares of the medical research company’s stock worth $1,813,000 after purchasing an additional 339 shares during the period. Finally, Procyon Advisors LLC raised its stake in Thermo Fisher Scientific by 22.1% during the first quarter. Procyon Advisors LLC now owns 12,146 shares of the medical research company’s stock worth $7,059,000 after purchasing an additional 2,196 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have commented on TMO shares. Evercore ISI lifted their target price on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a research note on Thursday, April 4th. HSBC boosted their price target on shares of Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a “buy” rating in a research note on Tuesday, April 30th. JPMorgan Chase & Co. boosted their price target on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a research note on Thursday, April 25th. Citigroup began coverage on shares of Thermo Fisher Scientific in a research note on Monday, March 18th. They issued a “neutral” rating and a $620.00 price target on the stock. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $650.00 price target (up from $600.00) on shares of Thermo Fisher Scientific in a research note on Monday, June 3rd. Five investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $607.06.

Thermo Fisher Scientific Trading Up 0.4 %

NYSE TMO opened at $552.72 on Friday. The company has a quick ratio of 1.33, a current ratio of 1.70 and a debt-to-equity ratio of 0.68. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $603.82. The stock has a market capitalization of $210.98 billion, a PE ratio of 35.45, a price-to-earnings-growth ratio of 2.57 and a beta of 0.79. The firm has a 50 day moving average of $574.84 and a two-hundred day moving average of $562.59.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, topping the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. The company had revenue of $10.35 billion during the quarter, compared to analysts’ expectations of $10.14 billion. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 21.65 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, July 15th. Stockholders of record on Friday, June 14th will be issued a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 0.28%. The ex-dividend date is Friday, June 14th. Thermo Fisher Scientific’s payout ratio is 10.01%.

Insider Activity

In other news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $567.28, for a total value of $5,672,800.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares in the company, valued at approximately $70,238,340.48. The sale was disclosed in a document filed with the SEC, which is available at this link. In related news, SVP Michael A. Boxer sold 2,000 shares of the company’s stock in a transaction on Friday, April 26th. The shares were sold at an average price of $567.94, for a total value of $1,135,880.00. Following the completion of the sale, the senior vice president now owns 13,083 shares in the company, valued at approximately $7,430,359.02. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $567.28, for a total transaction of $5,672,800.00. Following the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at approximately $70,238,340.48. The disclosure for this sale can be found here. In the last quarter, insiders sold 22,000 shares of company stock worth $12,532,780. Corporate insiders own 0.34% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.